Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT).

ABSTRACT:

Introduction

Lowering blood pressure (BP) reduces the risk for cognitive impairment and the progression of cerebral white matter lesions. It is unclear whether hypertension control also influences plasma biomarkers related to Alzheimer's disease and non-disease-specific neurodegeneration.

Methods

We examined the effect of intensive (< 120 mm Hg) versus standard (< 140 mm Hg) BP control on longitudinal changes in plasma amyloid beta (Aβ)₄₀ and Aβ₄₂ , total tau, and neurofilament light chain (NfL) in a subgroup of participants from the Systolic Blood Pressure Intervention Trial (N = 517).

Results

Over 3.8 years, there were no significant between-group differences for Aβ_40, Aβ_42, Aβ₄₂ /Aβ_40, or total tau.

SUBMITTER: Pajewski NM 

PROVIDER: S-EPMC9110563 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature